GALDERMA
Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation roadmap.
The license updates, issued following the agency’s good manufacturing practices (GMP) inspection of Galderma’s center of excellence in Uppsala, Sweden, enable Galderma to manufacture and perform bioanalytical testing on RelabotulinumtoxinA (QM1114). One of Galderma’s key innovation pipeline assets in Injectable Aesthetics, RelabotulinumtoxinA is a next-generation liquid neuromodulator in Injectable Aesthetics developed using Galderma’s proprietary PEARL™ technology. This technology preserves the molecule’s integrity, resulting in a highly active, complex-free botulinum toxin A.
“Our commitment to leading innovation in dermatology is reflected in our high-performance operations. These new license updates granted by the Swedish authorities reflect Galderma’s skills and the capacities we are building to support our rapid growth trajectory. As we work to extend our category leadership globally, these new capabilities will increase Galderma’s autonomy to manufacture and commercialize the next generation of scientifically differentiated innovations in dermatology.”
ADRIAN MURPHY HEAD OF GLOBAL OPERATIONS GALDERMA
|
Galderma’s center of excellence in Uppsala is one of the company’s four state-of-the-art manufacturing and R&D facilities around the world. Galderma is currently expanding this site in response to growing global demand for science-based premium dermatology solutions. The new facility—scheduled for completion by the end of 2025—will be strategically positioned to cater to the higher demand for injectable aesthetics treatments worldwide and the development of upcoming products. With a modular design that allows for seamless further expansion in the future, this forward-looking approach aligns with both Galderma’s growth strategy and its environment, social and governance (ESG) roadmap.
About RelabotulinumtoxinA (QM1114)
Developed by Galderma, RelabotulinumtoxinA is a highly active, innovative, complex-free and ready-to-use liquid botulinum toxin A with a proprietary strain. Manufactured using a unique state-of-the-art process, it is designed as a liquid. This avoids the need to reconstitute from powder and thus eliminates the variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally, with a view to expanding its neuromodulator portfolio – part of the broadest injectable aesthetics portfolio on the market.
About Galderma
Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618347979/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ares Management to Acquire BlueCove30.10.2025 09:18:00 CET | Press release
Integrated Business to Form Newly Created Ares Systematic Credit Strategy Ares Management Corporation (NYSE: ARES) (“Ares”) announced today that one of its affiliates has entered into a definitive agreement to acquire the entire outstanding share capital of BlueCove Limited (“BlueCove”), a London-based systematic fixed income manager. Financial terms were not disclosed. The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including regulatory approvals. Founded in 2018 by Alex Khein and Hugh Willis – who have respectively served as CEO and Executive Chairman – BlueCove has grown to become a leader in systematic credit investing. The firm is comprised of a highly experienced, long-tenured team of fixed income investment, engineering, and business infrastructure professionals specializing in systematic portfolio management. Through its proprietary technology and varied product offering, BlueCove invests in high-yield, corporate inves
Bybit Expands Partnership with Thredd to Globally Scale Multi-Currency Crypto-Linked Debit Cards30.10.2025 09:00:00 CET | Press release
Thredd, the leading next-generation global payments processor, today announced an expanded partnership with Bybit, the world’s second-largest cryptocurrency exchange by trading volume. The collaboration supports regional rollout of the Bybit Card—Bybit’s flagship multi-currency, crypto-linked payment card, bridging the gap between digital assets and everyday payments across key global markets. Thredd’s processing platform is built to scale and navigate regulatory requirements across regions. With a single connection, Bybit can configure market-specific programs that meet local compliance needs while retaining centralized visibility. This flexibility has enabled Bybit to rapidly expand across multiple markets with more on the horizon. Over 2 million users worldwide trust the Bybit Card for what matters most: competitive cardholder rewards, true global access, and effortless crypto-to-fiat convenience. Bybit leverages Thredd’s infrastructure to issue both virtual and physical Visa and Ma
Manhattan Associates Announces Appointment of Greg Betz As Chief Operating Officer30.10.2025 09:00:00 CET | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced the appointment of Greg Betz to the position of Chief Operating Officer. A seasoned executive, Betz brings broad experience leading complex, international organisations. Most recently, Greg led Microsoft FastTrack, an organisation of more than 1,000 engineers in 35 countries that deliver cloud conversions to Microsoft's largest cloud customers. “Greg is an accomplished executive with a proven track record of delivering operational excellence to transform businesses and drive growth,” said Eric Clark, president and CEO of Manhattan Associates. “His appointment is yet another proof point of our commitment to expanding the depth and experience of our team to drive faster cloud adoption, and I am confident that his forward-thinking, result-oriented approach will play a pivotal role in our next phase of rapid growth.” In his new position, Greg will play a key role in helping scale the operational frameworks around conversions and rene
Coats Completes Acquisition of OrthoLite, Strengthening Footwear Business30.10.2025 08:15:00 CET | Press release
Acquisition aligns with Coats’ Long-Term Growth Strategy in Apparel and Footwear Coats Group plc, a world-leading Tier 2 supplier of critical components to the apparel and footwear industries, announced today that it has completed its acquisition of OrthoLite, a global market leader in footwear materials and the number one brand in premium insoles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030015142/en/ OrthoLite Vietnam The acquisition marks a major milestone in the Company’s long-term growth plans and strengthens its existing footwear division through expansion into the attractive, high-growth premium insole segment. Both companies already have a similar customer base, a complementary global footprint and a commitment to industry-leading innovation and sustainability practices. “OrthoLite is one of the world’s most innovative manufacturers in footwear materials. With our combined capabilities, we’ll now be able to
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year30.10.2025 08:04:00 CET | Press release
First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% atActual Exchange Rates (AER),Impacted by Generic Erosion of VYVANSE® and FX HeadwindCore Operating Profit Declined 8.8% at CER in the First Half, Reflecting Revenue Performance and Product Mix; Impact Partially Offset by Operational EfficienciesFirst Half Reported Operating Profit (-27.7% at AER) Impacted by Impairment Losses Incurred in Q2 Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: “Takeda’s fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of transition to a new phase focusing on new product launches. Our updated full-year outlook reflects impairment charges associated with strategic pipeline decisions taken in Q2, as well as transactional FX. “Looking ahead, our curr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom